Treatment of Knee Osteoarthritis with Intraarticular Umbilical Cord-Derived Wharton's Jelly: A Case Report
We present the case of a 27-year-old male with grade II knee osteoarthritis (OA) that was intraarticularly injected with a 2 mL umbilical cord-derived Wharton's jelly (UC-derived WJ) formulation. The patients' baseline radiographs were taken and baseline numeric pain rating scale (NPRS), knee injury and osteoarthritis outcome score (KOOS), 7-point Likert scale, and a 36-item short form survey (SF-36) were recorded. The NPRS was re-recorded immediately after the injection, and at 24 h, 48 h, 1 week, 6 weeks, and at 3 months follow-up post-injection. The KOOS and 7-point Likert scale was re-recorded at the patients' 1week, 6 week, and 3month follow-up, and SF-36 was re-recorded at 3 months. A final set of X-rays were also performed at 3 months follow-up post-injection. No adverse effects from the injection were reported over the duration of the study. No significant difference nor progression in OA on X-rays compared to baseline was observed. NPRS decreased by 50% and the 7-point Likert scale increased to Extremely Satisfied. KOOS increased overall by 10% and the SF-36 overall change was 25%. These results indicate the potential application of UC-derived WJ in the treatment of knee OA. Larger, long term, non-randomized and randomized control trials are warranted to adequately assess the safety and efficacy of UC-derived WJ and ultimate clinical use.
Keywords: Wharton’s jelly; biologics; cytokines; exosomes; extracellular vesicles; growth factors; hyaluronic acid; knee osteoarthritis; regenerative medicine; umbilical cord.
Conflict of interest statement
A.G. is a consultant for BioIntegrate. H.J.L. and S.F.E.-A.III own equity in BioIntegrate. The remaining authors declare that they have no conflicts of interest. BioIntegrate has contributed to the design of the study, interpretation of data, and writing, editing and approval of the manuscript. Data was collected by an independent surgeon (A.G.P.) not employed by the funder. The decision to publish the findings was not influenced by the funder.